Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,618 across all filing types
Latest filing 2025-11-23 Regulatory Filings
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Topical Pan-Lox Inhibition for Skin Scarring KOL webinar 3 pages 198.0KB
Regulatory Filings Classification · 95% confidence The document is a media release from Syntara Limited announcing a webinar featuring a key opinion leader and company executives discussing a clinical-stage drug candidate and its development status. It includes details about the webinar, the drug's clinical trial phases, and company background. There are no financial statements, regulatory filings, voting results, or management changes. The content is promotional and informational about an upcoming event and product pipeline, not a financial report or regulatory filing. Therefore, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not fit other specific categories.
2025-11-23 English
Initiation of amsulostat Phase 2 MESSAGE trial in MDS 4 pages 173.9KB
Regulatory Filings Classification · 95% confidence The document is a media release announcing the initiation of a Phase 2 clinical trial for a drug candidate by Syntara Limited. It provides detailed information about the trial design, objectives, and collaborators, but it does not contain financial data, regulatory filings, or detailed financial performance reports. It is not an earnings release, annual report, or any form of financial or regulatory filing. The content is primarily a corporate announcement about a clinical trial commencement, which fits best under the category of a general regulatory announcement or miscellaneous corporate news. Given the absence of financial or governance details, the most appropriate classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories.
2025-11-20 English
Chair's Address to Shareholders 2 pages 157.6KB
AGM Information Classification · 95% confidence The document is a Chair's Address delivered at the 2025 Annual General Meeting of Syntara Limited. It contains a detailed message to shareholders reflecting on the company's clinical progress, regulatory updates, financial position, and strategic outlook. The content is typical of presentations or materials shared during an AGM rather than a formal annual report or financial statement. The document length is about 5606 characters, which is consistent with a speech or presentation rather than a full Annual Report (10-K). There is no detailed financial data or comprehensive financial statements included, which rules out classification as an Annual Report or Interim Report. The document is clearly linked to the AGM event and is a communication from the Chair to shareholders at that meeting. Therefore, the most appropriate classification is AGM Information (AGM-R).
2025-11-19 English
CEO Address to AGM and Shareholder Resolutions 37 pages 1.7MB
AGM Information Classification · 95% confidence The document is titled 'Annual General Meeting 20 November 2025' and contains detailed agenda items typical of an AGM, including presentations by the Board Chair and CEO, shareholder questions, and formal business such as adoption of the Remuneration Report and re-election of directors. It includes detailed biographies of board members, CEO presentations, and shareholder voting instructions. The content is consistent with materials shared during an Annual General Meeting rather than a full Annual Report or other filing types. The length (15,000 characters) and detailed content support it being AGM presentation materials rather than a brief announcement or a transcript. Therefore, the document fits the category of AGM Information (AGM-R).
2025-11-19 English
Results of AGM 2 pages 162.7KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement addressed to the Australian Securities Exchange regarding the outcomes of resolutions passed at the Annual General Meeting (AGM) of Syntara Limited held on 20 November 2025. It details the voting results for each resolution, including the adoption of the remuneration report, re-election of a director, and approval of grants to executives. The document references ASX Listing Rule 3.13.2, which pertains to the disclosure of meeting outcomes. The content is focused on the results of shareholder votes at the AGM rather than the full AGM materials or presentations. The document length is 3487 characters, which is relatively short and consistent with a voting results announcement rather than a full report or presentation. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-11-19 English
Positive opinion for Orphan Drug Designation in EU 2 pages 136.3KB
Regulatory Filings Classification · 95% confidence The document is a media release announcing that Syntara Limited has received a positive opinion for Orphan Drug Designation from the European Medicines Agency for its drug amsulostat. It discusses clinical trial results, regulatory feedback, and future trial plans. There are no financial statements, detailed financial performance data, or comprehensive report content. The document is a public announcement of a regulatory and clinical development milestone rather than a financial report or detailed investor presentation. It is not a report publication announcement since it does not mention the release or availability of a report, nor is it a certification or legal proceeding update. The content fits best as a general regulatory announcement about company progress and regulatory status, which aligns with the Regulatory Filings (RNS) category as a fallback for miscellaneous regulatory announcements that do not fit other categories.
2025-11-16 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.